Form 4: Tarsus CEO Sells Shares Under 10b5-1 Plan

Tarsus Pharmaceuticals CEO Bobak Azamian sold 6,000 shares of common stock for $55.37 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., reported a sale of common stock.
• The transaction involved 6,000 shares of common stock.
• The shares were sold at a weighted average price of $55.37 per share.
• The sale was executed on September 24, 2025.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following the sale, Azamian beneficially owns 812,106 shares indirectly through the Bobak Azamian Living Trust and 53,635 shares directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale, which is generally considered neutral. While insider selling can sometimes be viewed negatively, the existence of a 10b5-1 plan mitigates concerns about its implications for the company's future.

Positives

• The sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a reaction to recent company performance or news.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a slight negative by investors, though the impact is mitigated by the pre-planned nature.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe the insider sale, but the pre-planned nature under a 10b5-1 plan typically reduces concerns about management's confidence in the company's prospects.

Key Dates

Recommendation

The filing reports a routine insider stock sale by the CEO under a pre-established 10b5-1 trading plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a lack of confidence from management, as it is pre-scheduled. The volume of shares sold (6,000) is relatively small compared to the CEO's total beneficial ownership (over 860,000 shares), suggesting it is likely for personal financial planning rather than a bearish signal. Therefore, the filing itself does not provide sufficient new information to warrant a change from a 'hold' recommendation, assuming no other material news.

Keywords

Tarsus Pharmaceuticals, TARS, Bobak Azamian, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, Director